Side effects of medications used to treat childhood interstitial lung disease.
Identifieur interne : 000436 ( Ncbi/Merge ); précédent : 000435; suivant : 000437Side effects of medications used to treat childhood interstitial lung disease.
Auteurs : Oded Breuer [Australie] ; André Schultz [Australie]Source :
- Paediatric respiratory reviews [ 1526-0550 ] ; 2018.
Descripteurs français
- KwdFr :
- Antibactériens (effets indésirables), Antirhumatismaux (effets indésirables), Azithromycine (effets indésirables), Cyclophosphamide (effets indésirables), Enfant, Facteur de stimulation des colonies de granulocytes et de macrophages (effets indésirables), Glucocorticoïdes (effets indésirables), Humains, Hydroxychloroquine (effets indésirables), Immunosuppresseurs (effets indésirables), Méthotrexate (effets indésirables), Méthylprednisolone (effets indésirables), Pneumopathies interstitielles (traitement médicamenteux), Prednisolone (effets indésirables), Rituximab (effets indésirables), Utilisation hors indication.
- MESH :
- effets indésirables : Antibactériens, Antirhumatismaux, Azithromycine, Cyclophosphamide, Facteur de stimulation des colonies de granulocytes et de macrophages, Glucocorticoïdes, Hydroxychloroquine, Immunosuppresseurs, Méthotrexate, Méthylprednisolone, Prednisolone, Rituximab.
- traitement médicamenteux : Pneumopathies interstitielles.
- Enfant, Humains, Utilisation hors indication.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (adverse effects), Antirheumatic Agents (adverse effects), Azithromycin (adverse effects), Child, Cyclophosphamide (adverse effects), Glucocorticoids (adverse effects), Granulocyte-Macrophage Colony-Stimulating Factor (adverse effects), Humans, Hydroxychloroquine (adverse effects), Immunosuppressive Agents (adverse effects), Lung Diseases, Interstitial (drug therapy), Methotrexate (adverse effects), Methylprednisolone (adverse effects), Off-Label Use, Prednisolone (adverse effects), Rituximab (adverse effects).
- MESH :
- chemical , adverse effects : Anti-Bacterial Agents, Antirheumatic Agents, Azithromycin, Cyclophosphamide, Glucocorticoids, Granulocyte-Macrophage Colony-Stimulating Factor, Hydroxychloroquine, Immunosuppressive Agents, Methotrexate, Methylprednisolone, Prednisolone, Rituximab.
- drug therapy : Lung Diseases, Interstitial.
- Child, Humans, Off-Label Use.
Abstract
Interstitial lung disease in children (chILD) comprises a range of different rare diseases. There is limited evidence for the treatment of chILD and no randomised clinical trials of treatment have been undertaken. Most treatments are therefore prescribed off-label based on expert opinion. The off-label nature of prescription of drugs for chILD highlights the importance of a solid understanding of the side effects to facilitate risk-benefit assessment. The European Respiratory Society chILD guidelines recommend the use of systemic glucocorticosteroids, hydroxychloroquine and azithromycin. Side effects of these drugs will be discussed followed by consideration of other drugs used for the treatment of chILD.
DOI: 10.1016/j.prrv.2018.03.002
PubMed: 29627169
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000117
- to stream PubMed, to step Curation: 000117
- to stream PubMed, to step Checkpoint: 000090
Links to Exploration step
pubmed:29627169Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Side effects of medications used to treat childhood interstitial lung disease.</title>
<author><name sortKey="Breuer, Oded" sort="Breuer, Oded" uniqKey="Breuer O" first="Oded" last="Breuer">Oded Breuer</name>
<affiliation wicri:level="1"><nlm:affiliation>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth</wicri:regionArea>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schultz, Andre" sort="Schultz, Andre" uniqKey="Schultz A" first="André" last="Schultz">André Schultz</name>
<affiliation wicri:level="1"><nlm:affiliation>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia; School of Paediatric and Child Health, University of Western Australia, Australia. Electronic address: andre.schultz@health.wa.gov.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia; School of Paediatric and Child Health, University of Western Australia</wicri:regionArea>
<wicri:noRegion>University of Western Australia</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29627169</idno>
<idno type="pmid">29627169</idno>
<idno type="doi">10.1016/j.prrv.2018.03.002</idno>
<idno type="wicri:Area/PubMed/Corpus">000117</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000117</idno>
<idno type="wicri:Area/PubMed/Curation">000117</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000117</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000090</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000090</idno>
<idno type="wicri:Area/Ncbi/Merge">000436</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Side effects of medications used to treat childhood interstitial lung disease.</title>
<author><name sortKey="Breuer, Oded" sort="Breuer, Oded" uniqKey="Breuer O" first="Oded" last="Breuer">Oded Breuer</name>
<affiliation wicri:level="1"><nlm:affiliation>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth</wicri:regionArea>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schultz, Andre" sort="Schultz, Andre" uniqKey="Schultz A" first="André" last="Schultz">André Schultz</name>
<affiliation wicri:level="1"><nlm:affiliation>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia; School of Paediatric and Child Health, University of Western Australia, Australia. Electronic address: andre.schultz@health.wa.gov.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia; School of Paediatric and Child Health, University of Western Australia</wicri:regionArea>
<wicri:noRegion>University of Western Australia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Paediatric respiratory reviews</title>
<idno type="eISSN">1526-0550</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (adverse effects)</term>
<term>Antirheumatic Agents (adverse effects)</term>
<term>Azithromycin (adverse effects)</term>
<term>Child</term>
<term>Cyclophosphamide (adverse effects)</term>
<term>Glucocorticoids (adverse effects)</term>
<term>Granulocyte-Macrophage Colony-Stimulating Factor (adverse effects)</term>
<term>Humans</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Immunosuppressive Agents (adverse effects)</term>
<term>Lung Diseases, Interstitial (drug therapy)</term>
<term>Methotrexate (adverse effects)</term>
<term>Methylprednisolone (adverse effects)</term>
<term>Off-Label Use</term>
<term>Prednisolone (adverse effects)</term>
<term>Rituximab (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (effets indésirables)</term>
<term>Antirhumatismaux (effets indésirables)</term>
<term>Azithromycine (effets indésirables)</term>
<term>Cyclophosphamide (effets indésirables)</term>
<term>Enfant</term>
<term>Facteur de stimulation des colonies de granulocytes et de macrophages (effets indésirables)</term>
<term>Glucocorticoïdes (effets indésirables)</term>
<term>Humains</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Immunosuppresseurs (effets indésirables)</term>
<term>Méthotrexate (effets indésirables)</term>
<term>Méthylprednisolone (effets indésirables)</term>
<term>Pneumopathies interstitielles (traitement médicamenteux)</term>
<term>Prednisolone (effets indésirables)</term>
<term>Rituximab (effets indésirables)</term>
<term>Utilisation hors indication</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antirheumatic Agents</term>
<term>Azithromycin</term>
<term>Cyclophosphamide</term>
<term>Glucocorticoids</term>
<term>Granulocyte-Macrophage Colony-Stimulating Factor</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Methotrexate</term>
<term>Methylprednisolone</term>
<term>Prednisolone</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antibactériens</term>
<term>Antirhumatismaux</term>
<term>Azithromycine</term>
<term>Cyclophosphamide</term>
<term>Facteur de stimulation des colonies de granulocytes et de macrophages</term>
<term>Glucocorticoïdes</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Méthotrexate</term>
<term>Méthylprednisolone</term>
<term>Prednisolone</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Pneumopathies interstitielles</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Humans</term>
<term>Off-Label Use</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Enfant</term>
<term>Humains</term>
<term>Utilisation hors indication</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Interstitial lung disease in children (chILD) comprises a range of different rare diseases. There is limited evidence for the treatment of chILD and no randomised clinical trials of treatment have been undertaken. Most treatments are therefore prescribed off-label based on expert opinion. The off-label nature of prescription of drugs for chILD highlights the importance of a solid understanding of the side effects to facilitate risk-benefit assessment. The European Respiratory Society chILD guidelines recommend the use of systemic glucocorticosteroids, hydroxychloroquine and azithromycin. Side effects of these drugs will be discussed followed by consideration of other drugs used for the treatment of chILD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29627169</PMID>
<DateCompleted><Year>2019</Year>
<Month>04</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>04</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-0550</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>28</Volume>
<PubDate><Year>2018</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Paediatric respiratory reviews</Title>
<ISOAbbreviation>Paediatr Respir Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Side effects of medications used to treat childhood interstitial lung disease.</ArticleTitle>
<Pagination><MedlinePgn>68-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1526-0542(18)30046-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prrv.2018.03.002</ELocationID>
<Abstract><AbstractText>Interstitial lung disease in children (chILD) comprises a range of different rare diseases. There is limited evidence for the treatment of chILD and no randomised clinical trials of treatment have been undertaken. Most treatments are therefore prescribed off-label based on expert opinion. The off-label nature of prescription of drugs for chILD highlights the importance of a solid understanding of the side effects to facilitate risk-benefit assessment. The European Respiratory Society chILD guidelines recommend the use of systemic glucocorticosteroids, hydroxychloroquine and azithromycin. Side effects of these drugs will be discussed followed by consideration of other drugs used for the treatment of chILD.</AbstractText>
<CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Breuer</LastName>
<ForeName>Oded</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schultz</LastName>
<ForeName>André</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Telethon Kids Institute, University of Western Australia, Perth, Australia; Princess Margaret Hospital for Children, Perth, Australia; School of Paediatric and Child Health, University of Western Australia, Australia. Electronic address: andre.schultz@health.wa.gov.au.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>03</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Paediatr Respir Rev</MedlineTA>
<NlmUniqueID>100898941</NlmUniqueID>
<ISSNLinking>1526-0542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber>
<NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83869-56-1</RegistryNumber>
<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8N3DW7272P</RegistryNumber>
<NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
<NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber>
<NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
<NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Azithromycin</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">Interstitial lung disease in children (chILD)</Keyword>
<Keyword MajorTopicYN="N">Medication side effects</Keyword>
<Keyword MajorTopicYN="N">Prednisolone</Keyword>
<Keyword MajorTopicYN="N">Pulse methylprednisolone</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>03</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>03</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>4</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29627169</ArticleId>
<ArticleId IdType="pii">S1526-0542(18)30046-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.prrv.2018.03.002</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Breuer, Oded" sort="Breuer, Oded" uniqKey="Breuer O" first="Oded" last="Breuer">Oded Breuer</name>
</noRegion>
<name sortKey="Schultz, Andre" sort="Schultz, Andre" uniqKey="Schultz A" first="André" last="Schultz">André Schultz</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000436 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000436 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:29627169 |texte= Side effects of medications used to treat childhood interstitial lung disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:29627169" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |